GCL
ASBP

Glazer Capital LLC’s Aspire Biopharma ASBP Stock Holding History

Glazer Capital LLC’s Portfolio ASBP Stock Details ASBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-33
Closed -$439K – 141
2024
Q1 		$439K Buy
33
+7
+27% +$92.1K 0.05% 103
2023
Q4 		$334K Buy
+26
New +$342K 0.03% 121
2023
Q2 		– Sell
-1,850
Closed -$23.3M – 230
2023
Q1 		$23.3M Sell
1,850
-4
-0.2% -$50K 1.27% 14
2022
Q4 		$22.9M Buy
1,854
+94
+5% +$1.15M 0.59% 61
2022
Q3 		$21.4M Buy
1,760
+58
+3% +$700K 0.39% 75
2022
Q2 		$20.4M Buy
+1,702
New +$20.4M 0.51% 51

Other funds holding ASBP

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Glazer Capital LLC's ASBP Position: Q2 2024 in Review

Glazer Capital LLC sold out of Aspire Biopharma (ASBP) in Q2 2024, closing a stake of 33 shares — an estimated $439K sold.

Glazer Capital LLC first reported a position in ASBP in Q2 2022 and held it in 6 quarters. The position peaked at $23.3M in Q1 2023. 3 funds tracked by Wall St. Rank hold ASBP as of Q2 2024.

  • Glazer Capital LLC reported no remaining Aspire Biopharma position as of Q2 2024 after selling out during the quarter.
  • Glazer Capital LLC sold 33 Aspire Biopharma shares in Q2 2024, an estimated $439K.
  • Glazer Capital LLC first reported a position in Aspire Biopharma in Q2 2022 and held it in 6 quarters.
  • Glazer Capital LLC's Aspire Biopharma position peaked at $23.3M in Q1 2023.
  • 3 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2024.

Based on Glazer Capital LLC's 13F filing for Q2 2024, filed 14 Aug 2024.